Kamishoyosan eases several premenstrual symptoms in an exploratory randomized trial
A Japanese Kampo formula, kamishoyosan (KSS), reduced premenstrual symptom burden in an exploratory open-label randomized trial of patients with premenstrual syndrome. Over three menstrual cycles, the treatment arm showed improvement in the primary endpoint, the premenstrual Menstrual Distress Questionnaire total score, along with better scores across multiple symptom domains and a lower Work Productivity and Activity Impairment activity score.
The signal was not confined to one symptom cluster. KSS was associated with improvement in pain, concentration, behavioral change, and negative feelings during the premenstrual phase, and hyperthymia declined during menstruation. In practical terms, the pattern suggests benefit across both emotional and physical dimensions of PMS rather than a narrow effect on mood alone.
Symptom relief extended from the luteal phase into menstruation
Premenstrual syndrome remains a broad clinical problem because it reaches beyond discomfort. Mood symptoms, abdominal bloating, pain, irritability, and sleep disruption can spill into work, school, and family life, making a treatment effect clinically meaningful only if it touches day-to-day function. The trial used the Menstrual Distress Questionnaire as its primary readout, and that measure improved after KSS treatment in the premenstrual period.
The secondary findings broadened the picture. KSS also reduced MDQ scores during the menstrual cycle, which matters because some therapies blunt premenstrual symptoms without changing the experience of menstruation itself. Here, the response appeared to track across the cycle, suggesting a more sustained effect on menstruation-associated distress. Daily symptom reporting reinforced the same direction of benefit, with reductions in irritability, easy anger, anxiety, emotional instability, abdominal distension, coldness, and stiff shoulders.
That mix of symptoms fits the way PMS presents at the bedside: not as a single syndrome with a single complaint, but as a moving set of neuropsychological and somatic changes that often peak before bleeding begins and then recede. A treatment that calms emotional volatility while also easing bloating and musculoskeletal discomfort may offer a more realistic path to patient-perceived improvement than a therapy aimed at one symptom alone.
Functional impairment moved in the same direction as symptom scores
The work and activity domain deserves its own attention. The Work Productivity and Activity Impairment activity impairment score was lower in the KSS group, which suggests the symptom changes were not limited to questionnaire data in isolation. For many patients with PMS, the clinical threshold for a useful intervention is whether it helps them function through ordinary obligations without feeling overwhelmed by pain, irritability, or fatigue.
An overall impression also favored KSS treatment. That finding does not replace symptom scoring, but it does reflect how patients often judge whether a therapy is worthwhile. Relief that is visible on paper yet absent in lived experience is of limited value; here, both moved in the same direction.
A single sentence captures the clearest safety result: the only adverse event related to KSS was headache in one case.
Safety signals were limited in this small open-label study
The safety profile was reassuring within the confines of this exploratory trial. One headache attributed to KSS was the only treatment-related adverse event mentioned, and no broader safety pattern emerged from the abstracted results. For a symptom syndrome that frequently requires repeated or cyclical treatment, tolerability can determine whether patients remain on therapy after the first attempt.
Still, the design shapes how far the findings can travel. This was an open-label randomized controlled trial, which means expectations from participants and investigators could influence reported symptom experience. The study enrolled 50 patients, enough to generate an early efficacy signal but not enough to settle comparative effectiveness or long-term safety. The abstract also does not provide the full distribution of baseline characteristics, the magnitude of change in each symptom subscale, or whether the treatment effect persisted beyond the three menstrual cycles studied.
Why a Kampo formula could plausibly affect PMS symptoms
Kamishoyosan has been used in Japanese practice for neuropsychiatric symptoms such as anxiety and irritability, along with physical symptoms linked to hormonal change around menstruation and menopause. That clinical positioning is relevant because PMS is thought to reflect a complex interaction between ovarian hormone fluctuations and central nervous system sensitivity, with downstream effects on mood, pain perception, and autonomic symptoms. A multicomponent Kampo formula may therefore be biologically plausible in a syndrome that rarely presents as one isolated complaint.
The symptom pattern in this trial fits that logic. Improvement in negative feelings, anxiety, irritability, and concentration points toward a central effect on affective and cognitive symptoms, while reduced abdominal distension, coldness, and stiff shoulders suggests a broader impact on bodily discomfort. If a therapy can reduce both emotional reactivity and physical strain, the functional consequences may be larger than any single score suggests.
What the trial can and cannot establish
This study supports the possibility that KSS may help patients with PMS, but it does not establish it as a standard of care. Open-label design leaves room for expectancy effects, and the small sample size limits confidence in the size and durability of benefit. The abstract also does not clarify how KSS compares with established therapies such as oral contraceptives, low-dose estrogen/progestin formulations, or selective serotonin reuptake inhibitors, all of which remain part of the current treatment conversation.
The most useful reading of the trial is as an early clinical signal. KSS improved the primary symptom score, reduced several prespecified symptom domains, lowered activity impairment, and produced few reported adverse effects. The next question is not whether the formula can move questionnaire scores in a small cohort, but how robust that benefit remains in a larger, blinded study with longer follow-up and clearer comparison against conventional PMS therapies.